

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Karen M. Templeton-Somers at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 15, 2002.

Linda Arey Skladany,

Senior Associate Commissioner for External Relations.

[FR Doc. 02-29808 Filed 11-22-02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Indian Women's Health Demonstration Program for American Indians and Alaska Natives

AGENCY: Indian Health Service, HHS.

ACTION: Extension of deadlines for competitive applications for the Indian Women's Health Demonstration Program for American Indians and Alaska Natives.

The Notice of funding availability for competitive grants for Indian Women's Health Demonstration Program for American Indians and Alaska Natives was published at 67 FR 66410 on October 31, 2002.

The Indian Health Service announces the extension of dates for the following:

1. *Application Receipt Date:* January 3, 2003.
2. *Application Review:* January 23-24, 2003.
3. *Applicants Notified of Results (approved, approved unfunded, or disapproved):* February 13, 2003.
4. *Anticipated Start of Grant Cycle:* March 1, 2003.

Applicants are notified in writing on or about February 13, 2003.

This extension provides applicants approximately four additional weeks to prepare and submit competitive applications.

All other information contained in **Federal Register** announcement remains unchanged.

Dated: November 18, 2002.

Charles W. Grimm,

Assistant Surgeon General, Interim Director, Indian Health Service.

[FR Doc. 02-29865 Filed 11-22-02; 8:45 am]

BILLING CODE 4160-16-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health (NIH).

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

Name of Committee: Advisory Committee to the Director, NIH.

Date: December 5, 2002.

Open: 8 a.m. to 12 p.m.

Agenda: Among the topics proposed for discussion are: (1) Current issues (2) advice on priority areas for the NIH Director and (3) a summary of future action items and follow up items.

Place: National Institutes of Health, 9000 Rockville Pike, Conference Room 6, Building 31C, Bethesda, MD 20892.

Closed: 1 p.m. to 5 p.m.

Agenda: Review and evaluate confidential budgetary items.

Place: National Institutes of Health, 9000 Rockville Pike, Conference Room 6, Building 31C, Bethesda, MD 20892.

Contact Person: Ruth L. Kirschstein, M.D., Deputy Director, NIH, National Institutes of Health, 1 Center Drive MSC 0148, Building 1, Room 126, Bethesda, MD 20892-0148, 301-496-2433, rk25n@nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

Information is also available on the home page: <http://www.nih.gov/about/director/acd.htm>, where an agenda and any additional information for the meeting will be posted when available.

Dated: November 15, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-29840 Filed 11-22-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Advisory Board, December 4, 2002, 8:45 a.m. to December 5, 2002, 12 p.m., which was published in the **Federal Register** on November 8, 2002, 67 FR 68148.

The meeting time has been changed to start at 8:30 a.m. on Wednesday, December 4, 2002. The Subcommittee on Planning and Budget meeting which was scheduled on Wednesday, December 4, 2002 has been cancelled. The meeting is partially closed to the public.

Dated: November 15, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-29842 Filed 11-22-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel. Cooperative Clinical Trial for Pediatric Transplantation.